Treatment with ticagrelor alone results in a lower rate of clinically relevant bleeding compared with ticagrelor and aspirin among patients with an acute coronary syndrome who had percutaneous coronary intervention and remained event-free for one month on dual antiplatelet therapy, according to a study published online April 7 in The Lancet to coincide with the annual meeting of the American College of Cardiology…
